Moderna launches clinical trial for HIV vaccine that uses mRNA technology
Moderna confirmed that the first participants have been dosed with its experimental HIV vaccine, kicking off its Phase 1 study.
In an announcement on 27 January, it stated that it had partnered with the International AIDS Vaccine Initiative (IAVI) to work on the jab.
Just like its highly effective COVID-19 vaccine, Moderna’s HIV shot uses mRNA (also known as messenger RNA) technology which helps the body make proteins that trigger immune responses.
The first doses in its clinical trial were administered at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C., with the first phase aiming to build on the response seen in Moderna’s proof-of-concept trial. “We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform.
